Cancer, Rare Disease Drugs To Be Covered As China Expands Reimbursement
China's national reimbursement drug list will undergo a much anticipated expansion in 2019, and therapies for cancer, pediatric and rare conditions from international firms including Roche and Actellion are likely to receive long-awaited coverage.
You may also be interested in...
China's main drug regulatory agency is hoping to tell its story to the world via a new English website, while the vaccines and other sectors are poised to see increasing quality inspections as the country builds up a new two-level scheme. Provincial reimbursement lists are also being halted.
Products old, new and reimbursed were the driving force for foreign drug firms including AstraZeneca, Merck and Pfizer and Sanofi to smash growth in China in the first quarter.
By avoiding crowded space and focusing instead on therapeutic areas with large potential, China remains attractive for drug developers, notes a recent white paper from investment bank China E-Capital.